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Assessment of adrenoleukodystrophy
lesions by high field MRS in non-sedated
pediatric patients
G. Öz, PhD; I. Tká, PhD; L.R. Charnas, MD, PhD; I.Y. Choi, PhD; K.J. Bjoraker, PhD; E.G. Shapiro, PhD;
and R. Gruetter, PhD
Abstract—Background: Early detection of white matter lesions in childhood-onset cerebral adrenoleukodystrophy (ALD)
is important as hematopoietic cell transplantation (HCT), currently the only effective treatment, is beneficial only if
performed early in the disease course. Objective: To establish reliable biochemical markers of cerebral disease progression
in patients with ALD to aid in treatment planning. Methods: The authors used proton magnetic resonance spectroscopy
(MRS) in combination with LCModel analysis to quantify brain metabolites in small volumes (3 to 16 mL) in the occipital
and frontal white matter and the splenium of the corpus callosum of 17 unsedated patients and 26 healthy volunteers
(adult n  21, age-matched n  5) at 4 tesla. Results: Absolute concentrations of 12 metabolites were reliably determined,
seven of which were established as markers of lesion development. Among these, creatine and choline containing
compounds were the weakest markers while N-acetylaspartate, glutamine, and lipids  lactate were the strongest. The
large extent of changes in the markers enabled detection of early neurochemical changes in lesion formation prior to
detection of abnormalities by conventional MRI. Concentrations of a number of metabolites were also significantly
different between normal appearing white matter of patients and controls indicating biochemical alterations in the
absence of cerebral disease. Neurochemical improvements following HCT were measured in six patients. Conclusions: The
progression of adrenoleukodystrophy, as well as effectiveness of its treatment, can be assessed with high precision using
high field 1H magnetic resonance spectroscopy in individual patients without the need for sedation.
NEUROLOGY 2005;64:●●●–●●●
X-linked adrenoleukodystrophy (ALD) is a disorder
of -oxidation of very long chain fatty acids (VLCFA)
due to a defect in the ALDP (ALD protein) gene
product in the peroxisomal membrane.1 Saturated
VLCFA, particularly hexacosanoic (C26:0) and tetra-
cosanoic (C24:0) acids, accumulate in many organs,
particularly the adrenal gland and the brain.2 The
minimum prevalence of the biochemical abnormality
is 1 in 21,000 males.3 Several phenotypes exist, with
the most severe being childhood-onset cerebral form
(C-ALD), a progressive inflammatory demyelination
of the cerebral white matter (WM). Approximately
35% of the boys with elevated VLCFA (biochemical
ALD) develop C-ALD between 3 and 10 years of age.1
Once demyelination begins, progression of behav-
ioral, cognitive, and neurologic deficits leads to vege-
tative state or death within a few years without
effective treatment. The remaining boys will likely
develop adrenomyeloneuropathy (AMN), with slowly
progressive gait spasticity and sensory ataxia. This
phenotype presents with a mean age at onset of 28
years. The pathology of AMN is different than
C-ALD and is primarily a noninflammatory axonal
degeneration of upper motor neurons and large fiber
sensory pathways within spinal cord and peripheral
nerves.1 Forty percent of men with AMN also have or
develop cerebral involvement with inflammatory de-
myelination, similar to that seen in childhood.1
Biochemical ALD is easily diagnosed by elevated
fasting plasma VLCFA levels.4 However, there are
no reliable methods for predicting in whom C-ALD
will develop. Currently the only therapy for C-ALD,
hematopoietic cell transplantation (HCT; encompass-
ing both bone marrow and cord blood transplant), is
effective only if performed early in the course of cere-
bral disease.5 The effect of HCT on AMN is un-
known. In addition, the morbidity and mortality of
HCT are too great to use in asymptomatic boys with-
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out C-ALD. Similarly, HCT for boys with advanced
disease (performance IQ less than 80 in previously
normal boys) may exacerbate the disease progression
and lead to poor functional outcome and death.6
C-ALD is currently diagnosed by detection of hyper-
intense regions in T2-weighted MRI before neurologic
signs and symptoms.7-9 Gadolinium enhancement in
ALD WM lesions predicts disease progression.10 Mag-
netization transfer MRI divides WM lesions into differ-
ent zones, but adds no additional predictive value.11 A
technique identifying the transition between biochemi-
cal ALD and C-ALD before structural damage is de-
tected by imaging methods has the potential to
improve medical care.
Biochemical changes such as altered energy and
membrane metabolism and intercellular metabolite
trafficking (glutamate-glutamine shuttling) are
likely to be present before structural changes. Sev-
eral groups using MR spectroscopy (MRS) found bio-
chemical changes in the absence of abnormalities on
T2-weighted MRI.8,12-15 These changes were limited
to a few metabolites and their ratios (NAA, creatine,
choline) at 1.5 tesla. Changes with disease progres-
sion in a larger number of metabolites were observed
in pooled data sets at 2 tesla.9 We hypothesized that
changes in more metabolites than previously studied
would be quantified reliably with the higher sensitiv-
ity at 4 tesla. Furthermore, the measurement of
these changes in single patients would represent an
advance for disease monitoring.
We sought to establish neurochemical profiles of
lesions of patients with ALD in comparison to their
normal appearing WM (NAWM) and the WM of
healthy controls and to determine the potential of
high field MRS to detect early changes in this profile
before abnormalities in T2-weighted MRI.
Methods. Patients and control subjects. Seventeen boys, 4 to
13 years, with the biochemical defect for ALD were studied after
obtaining informed consent from their parents using procedures
approved by the Institutional Review Board: Human Subjects
Committee of the University of Minnesota. The mean age at the
first MRS examination was 7.2  1.5 years (mean  SD, range 4
to 9 years). Twelve of these boys were studied longitudinally ap-
proximately every 6 months with an average duration of follow-up
of 2.1  0.9 years (range 0.6 to 3.4 years). The remaining five boys
were studied once. Eight boys had normal MRI (T2-weighted and
FLAIR) with a MRI Severity Score of 0.16 Nine boys had WM
lesions visible as hyperintense regions in T2-weighted MRI. Six of
them received HCT and were scanned before and after the
transplantation.
Neurologic and neuropsychological examinations were per-
formed at each visit. No neurologic abnormalities related to ALD
were observed at baseline for any of the boys. Two boys had
pre-existing neurologic abnormalities unrelated to ALD. Neuro-
psychological abnormalities related to ALD were seen at baseline
in boys with hyperintense regions in T2-weighted MRI; however,
none of them was considered to have disease that was too ad-
vanced for HCT.
Subjects were given the option to watch movies using an audio/
visual system17 during data collection. No sedation was used. Dur-
ing the entire study, a nurse inside the magnet room was
monitoring the physiology of the subject by an attached pulse
oximeter (In vivo Research Inc., Orlando, FL).
Spectra were acquired from 21 healthy adults (age 26.5  8.7,
range 18 to 47 years) and 5 age-matched controls (age 10.4  2.6,
range 6 to 12 years).
MRS. All studies were performed on a 4 tesla, 90 cm bore
magnet (Oxford Magnet Technology, Oxford, UK) with an INOVA
console (Varian, Palo Alto, CA) and a standard body gradient coil
(Sonata, Siemens, Erlangen, Germany). A TEM volume coil18 was
used as the NMR transceiver. Following positioning of the subject
in the magnet, transverse multislice images were obtained with a
RARE sequence (repetition time [TR]  4 seconds, echo train
length  8, echo time [TE]  60 msec, 7 slices, 2 averages) for the
selection of the volume of interest (VOI). Localization of 1H MR
spectra was achieved using ultra-short echo STEAM spectroscopy
with TE  5 msec, mixing time TM  42 msec, and TR  4.5
seconds. Water suppression was achieved using eight variable
power RF pulses with optimized relaxation delays (VAPOR) which
were interleaved with outer volume suppression to improve local-
ization performance.19 All first- and second-order shims were ad-
justed using FASTMAP with echoplanar readout.20 For
longitudinal studies voxel positions were chosen consistently to
assess time dependent changes in the particular areas. Spectra
were typically acquired from three brain regions: occipital and
frontal WM (8 to 16 mL volumes, 5 to 6 minutes data acquisition)
and the splenium of the corpus callosum (3 to 10 mL volumes, 5 to
10 minutes data acquisition). A typical session in the magnet did
not exceed 50 minutes.
Spectra were acquired and saved as single scans, which were
individually frequency and phase corrected to minimize the effects
of motion on spectral linewidths and signal-to-noise ratio (S/N).
Scans that showed evidence for substantial motion were excluded
and the remaining scans summed. When insufficient S/N did not
permit correction of single acquisitions (such as in small voxels in
the corpus callosum), data were averaged over four to eight scans
and then corrected.
Spectral quantitation. The contribution of individual metabo-
lites to the in vivo spectrum was quantified using LCModel.21 In
this fully automatic method, the in vivo spectrum is modeled as a
linear combination of adequately line-broadened individual me-
tabolite spectra. The metabolites that are known to contribute to
brain spectra are provided in a basis set,22 which in the current
study included the following 20 compounds: Alanine (Ala), aspar-
tate (Asp), glycerophosphoryl-choline (GPC), phosphoryl-choline
(PCho), creatine (Cr), phosphocreatine (PCr), -aminobutyric acid
(GABA), glucose (Glc), glutamine (Gln), glutamate (Glu), glutathione
(GSH), myo-inositol (myo-Ins), lactate (Lac), N-acetylaspartate
(NAA), N-acetyl-aspartyl-glutamate (NAAG), phosphorylethano-
lamine (PE), scyllo-inositol (scyllo-Ins), taurine (Tau), lipids, and
macromolecules. The model metabolite spectra were obtained by
simulation using previously reported chemical shifts and coupling
constants.23 The macromolecule pattern was obtained by averag-
ing inversion recovery spectra from the WM of five healthy sub-
jects, where the STEAM parameters were optimized to null the
metabolite resonances (TR  2 seconds, inversion time  0.675
seconds). The pattern of the lipid model spectrum was established
as follows: first, the two primary fatty acid resonances at 0.9
(methyl) and 1.3 ppm (methylene, (CH2)n) were quantified in
three in vivo spectra where the lipid contribution was strongest.
The signal intensity ratio of the methyl and methylene peaks was
very similar between these spectra; therefore the methyl-to-
methylene ratio in the final lipid model spectrum was set to the
average value (0.57) obtained from these three spectra. Intensities
of the smaller peaks at 1.60, 2.05, and 2.24 ppm were based on
literature24 and fatty acid structure. Attempts to fit a peak at 2.8
ppm, where polyunsaturated fatty acids display a signal, indicated
no contribution to the spectra at this chemical shift. The lipid
concentrations were based on the methyl peak at 0.9 ppm assum-
ing one methyl group per fatty acyl moiety.
The intensity of the in vivo spectrum was calibrated using the
water signal from the same voxel as an internal reference,25 as-
suming a water content of 72% for WM.26
Assessment of reliability in metabolite concentrations and sta-
tistical analysis. The criteria to select the reliable metabolite
concentrations were based on the Cramér-Rao lower bounds
(CRLB), which are estimates of the SD of the fit for each metabo-
lite and are also determined by LCModel. Only results with a
CRLB  50% were included in the analysis. Concentrations with
CRLB  50% were classified as not detected. Only metabolites
that had a CRLB below 50% in more than 70% of the spectra were
included in the neurochemical profile. If the covariance between
two metabolites was consistently high (correlation coefficient
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0.5), such as in the case of Cr and PCr, we chose to report their
sum (table 1) even though their individual values were estimated
by LCModel.
The concentrations of metabolites in healthy and lesioned tis-
sue were compared using the two-tailed, unpaired Student’s t test.
Results. Constituents of the neurochemical profile of non-
sedated patients and controls. When studying non-
sedated children, motion of the subject is a frequent
problem that reduces reliability of metabolite quantifica-
tion. We found that spectral intensity losses can be as high
as 30 to 40% due to scan-to-scan phase and frequency
changes. Phase and frequency correction of individual
scans eliminated these losses. The correction scheme was
verified by acquiring spectra from the same brain region in
the presence and absence of motion and identical concen-
trations were obtained from these spectra upon applying
the single scan correction.
Absolute metabolite concentrations in three known sites
of ALD lesions, namely occipital and frontal WM and cor-
pus callosum, were determined by deconvolution of the in
vivo 1H MR spectra into model spectra of 20 metabolites.
In addition to compounds previously described to contrib-
ute to spectra,22 the contribution of lipid signals was as-
sessed because spectra from lesions displayed fatty acid
peaks at 0.9 and 1.3 ppm, in some cases comparable in
intensity to creatine. The inclusion of lipids in the basis set
resulted in significant improvement of the LCModel fit (as
judged by CRLB, residuals and baseline) in all lesions.
Conversely, omission of the lipid model spectrum from the
basis set resulted in overestimation of lactate and macro-
molecule contributions in lesions.
The reliability of obtained concentrations was judged
based on Cramér-Rao lower bounds (see Methods for crite-
ria). Of the 20 compounds analyzed, Ala and GABA were
excluded and scyllo-Ins, Asp, and PE were considered bor-
derline reliable. Substantial covariance of concentrations
was found in five cases, so that NAA  NAAG, Cr  PCr,
GPC  PCho (from here on referred to as NAA, Cr, and
Cho), Lipid  Lac, and Glc  Tau were included in the
neurochemical profile instead of the concentrations of indi-
vidual compounds. Therefore 12 statistically independent
concentrations were evaluated (see table 1). The metabo-
lite concentrations in the frontal WM and corpus callosum
were similar to those in the occipital WM. Similarly, the
average CRLB values in frontal WM were comparable to
occipital WM. The CRLB in the corpus callosum were
somewhat higher due to the lower S/N in the smaller VOIs.
Neurochemical alterations in cerebral and non-cerebral
(biochemical) ALD. Proton MR spectra acquired from
WM lesions of patients with C-ALD displayed extensive
changes when compared to those from the NAWM of pa-
tients with ALD (figure 1), as well as control subjects.
NAA, Cr, and Glu were significantly lower and Cho, myo-
Ins, Gln, and Lipid  Lac were higher in lesions than both
NAWM of patients and healthy controls (see table 1). The
concentrations of three of these lesion markers (NAA, Gln,
Lipid  Lac) were more than two SDs different than con-
trols in all lesions in occipital WM, demonstrating the sen-
sitivity of the MRS method to identify cerebral disease.
The ratio of Glu-to-Gln was compared to the Cho-to-Cr
ratio, which has been extensively used as a disease mark-
er.12,14 Cho-to-Cr was only 50% higher in lesions in the
frontal and occipital WM while Glu-to-Gln was three- to
fourfold lower (figure 2). The difference in the Cho-to-Cr
ratio between lesion and control values in the splenium of
the corpus callosum did not reach statistical significance.
Table Average concentrations and Crame´r-Rao lower bounds (CRLB) of cerebral metabolites in the occipital white matter
Metabolite
Concentration, 	mol/g, mean  SD
No. lesions outside
95% CI† Average CRLB, %
Lesion,*
n  7
NAWM,
n  35
Adult controls,
n  18
NAA  NAAG 4.8  1.8‡ 9.5  0.6 11.4  1.3 7 3
Cr  PCr 6.0  0.8§ 6.7  0.5 7.1  0.8 2 4
GPC  PCho 2.6  0.4§ 2.1  0.3 2.0  0.4 3 5
myo-Inositol 9.8  2.7‡ 6.5  1.0 6.3  0.7 5 4
Glutamate 4.4  1.4‡ 7.1  0.9 6.7  0.8 5 7
Glutamine 4.8  2.3‡ 2.0  0.6 1.7  0.4 7 17
Lipid  lactate 11.8  5.5‡ 1.4  0.5 0.9  0.4 7 18
Glc  Tau 4.0  0.7 3.7  0.6 2.8  0.6 13
Glutathione 1.5  0.3 1.4  0.3 1.1  0.1 16
PE 2.0  1.1 1.7  0.6 1.0  0.4 27
scyllo-Inositol 0.3  0.1 0.3  0.1 0.4  0.1 30
Aspartate 2.1  0.2 1.8  0.5 1.2  0.4 33
* Data acquired from lesions before hematopoietic cell transplantation.
† Number of lesions that were more than 2 SD different from the adult control values; i.e., outside the 95% CI.
‡ p  0.0001 Lesion vs both NAWM and control.
§ p  0.01 Lesion vs both NAWM and control.
 p  0.03 Control vs both NAWM and lesion.
NAWM  normal-appearing white matter; NAA  N-acetylaspartate; NAAG  N-acetyl-aspartyl-glutamate; Cr  creatine; PCr 
phosphocreatine; GPC  glycerophosphoryl-choline; Glc  glucose; Tau  taurine; PE  phosphorylethanolamine.
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Conversely, the Glu-to-Gln ratio in the corpus callosum
lesions was threefold lower than controls (p  0.003), as
in the frontal and occipital WM lesions.
The distribution of metabolite concentrations among
subject groups was further assessed by analyzing correla-
tion plots of metabolite concentrations, such as Gln vs Glu
and Lipid  Lac vs myo-Ins (figure 3). The distribution of
metabolite concentrations in lesions was distinctly differ-
ent from that in NAWM as well as in adult and age-
matched controls. One lesion data point in the Gln vs Glu
plot (see figure 3B, circle) was close to those of controls,
but the other constituents of the neurochemical profile in
this voxel clearly indicated a lesion pattern.
Neurochemical differences were also detected between
NAWM of patients and controls (see table 1). For example,
no lipid contribution was measured in control brains, while
NAWM displayed significantly increased Lipid  Lac val-
ues. To determine if the differences observed were due to
the age difference between the patient and the control
group, data were acquired from five age-matched healthy
subjects. GSH, PE, and Glc  Tau were indeed different
between age-matched and adult controls (p  0.05).
Neurochemical changes in the transition from non-
cerebral to cerebral ALD. The two outlier data points in
the Lipid  Lac vs myo-Ins plot (figure 3A, circle) display
neurochemical changes due to lesion development that
were detected before appearance of abnormalities in T2-
weighted MRI. These data were acquired from NAWM of
patients who had lesions in other areas of the brain. In
both cases lesion progression into the VOI of the MRS
measurement became apparent only at subsequent MRI
examinations.
Another example of early detection of lesion develop-
ment is shown in figure 4. The frontal WM spectrum
shown was acquired from a region with borderline hyper-
intensity in the T2-weighted image, however, quantifica-
tion of this spectrum revealed a full lesion profile (low
NAA, Glu, high Cho, myo-Ins, Gln). This profile was con-
sistent with worsened anterior neuropsychological scores
(executive function, speed, motor, memory/learning).
Neurochemical changes following HCT. Six patients
with C-ALD were examined before and up to 2.3 years
after HCT. In addition to reduced Cho and stabilized or
somewhat reduced NAA values (with the exception of one
patient), these patients displayed normalized/reduced Gln
and Lipid  Lac concentrations (figure 5). Their Glu re-
mained low or decreased further and myo-Ins remained
high or increased further. The spectra of one of these pa-
tients after the HCT are shown in figure 4. While the
occipital WM spectrum was still very different from
healthy WM with the high myo-Ins and low NAA peaks,
Figure 1. Proton MR spectrum from the normal-
appearing white matter (NAWM) of a 6-year-old asymp-
tomatic patient with adrenoleukodystrophy (ALD) (A) in
comparison to the spectrum from a lesion of a 9-year-old
patient with cerebral ALD (B). The voxels in the occipital
WM are shown on the T2-weighted images, VOI in A was
16 mL and in B 8 mL. The major metabolite peaks are
labeled (Ins: myo-inositol, Cr: CrPCr, total creatine, Gln:
glutamine, Glu: glutamate, Cho: PChoGPC, choline
containing compounds, NAA: NAANAAG, total
N-acetylaspartate, Lac: lactate). Changes in the lesion are
shown with arrows.
Figure 2. Comparison of choline-to-creatine (A) and
glutamate-to-glutamine (B) concentration ratios in differ-
ent brain regions of patients (lesions, normal-appearing
white matter [NAWM]) and healthy adults. Cho refers to
GPC  PCho, Cr to PCr  Cr, OCC to occipital WM, FRO
to frontal WM, and CC to splenium of corpus callosum.
Error bars indicate SDs. *p  0.003 for lesion vs both
NAWM and healthy adult values.
balt4/znl-neurol/znl-neurol/znl00305/znl9349-05a simmsl S8 12/8/04 15:17 Art: 156612 Input-c
4 NEUROLOGY 64 February (1 of 2) 2005
F3
F4
F5
the improvement in the neurochemical profile was evident
from the normalized Cho-to-Cr ratio. Spectral quantitation
further revealed a reduction in Gln and Lipid  Lac. These
improvements were consistent with an improved posterior
neuropsychological score (visual and auditory perception).
Discussion. Quick, safe, precise, and reliable mea-
surement of disease markers in individuals is needed
to apply a method to patient monitoring. We describe
the reliable measurement of a 12-component neuro-
chemical profile with high precision in three WM
regions involved in early C-ALD in less than 1 hour.
We did not use sedation, which reduced both the risk
and the time and effort involved in each scan. This is
the first study where such an extensive neurochemi-
cal profile was assessed noninvasively in individual
patients to follow a neurologic condition.
Typically MRS studies of the brain evaluate three
to five metabolites (NAA, Cr, Cho, myo-Ins, Lac) or
their ratios, while we assessed concentrations of 12
metabolites, 7 of which were metabolic markers of
ALD lesions (see table 1). Measurement of absolute
concentrations avoids ambiguities associated with
relative measurements and although it is more prone
to averaging errors caused by motion, which occur
frequently in non-sedated children, we minimized
these potential errors by acquiring the spectra in
single scans. This approach substantially improved
the spectral quality (resolution and S/N) and the re-
liability of metabolite quantification and should be
applicable to 3 tesla magnets that are increasingly
being used in the clinical setting. At lower magnetic
fields, which preclude such an approach, statistically
Figure 3. Correlation plots of metabolite concentrations
in occipital white matter in different groups of subjects.
(A) Lipid  lactate vs myo-inositol; B) glutamine vs gluta-
mate. The large dynamic range of concentrations from
healthy to lesioned tissue is illustrated. Lesion data were
acquired before hematopoietic cell transplantation. The
outliers in A shown with a circle around them display
early neurochemical changes in lesion formation. The out-
lier in B (circle) was acquired from a lesion that displayed
the characteristic changes in the other markers (high Cho,
myo-Ins, Lipid  Lac, low NAA). NAWM  normal-
appearing white matter.
Figure 4. Proton MRS of a patient with cerebral adreno-
leukodystrophy after hematopoietic cell transplantation.
The voxels (16 mL) in the frontal and occipital white mat-
ter (WM) are shown on the T2-weighted image. The
lesioned occipital WM (B) shows an improved neurochemi-
cal profile as a result of transplant (reduced Cho, Gln,
Lipid  Lac), while the frontal WM (A) spectrum acquired
from a region with borderline MRI hyperintensity displays
a lesion pattern (reduced NAA, Glu, increased Cho, myo-
Ins, Gln).
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significant differences between subject groups may
be obscured.8 The high precision in our concentration
measurements was evident from the low CRLB (see
table 1). Changes greater than twice the CRLB can
be detected in individual spectra with 95% confi-
dence.27 For example, changes in Glu concentrations
of 14% are detectable with our protocol.
Abnormalities were identified using metabolite
correlation plots (see figure 3). There is tight distri-
bution of healthy control and NAWM values in the
Lipid  Lac vs myo-Ins plot. The lesion values are
more variable, likely because they represent differ-
ent disease stages. This suggests that lesion progres-
sion can be followed in individual patients with
C-ALD over time with our method. Indeed, we de-
tected neurochemical improvements in lesions of
each of the six patients after HCT (see figure 5).
Furthermore, we detected a starting lesion in the
NAWM of two patients (see figure 3A, circle) and a
full blown lesion in a region with borderline hyperin-
tensity in the T2-weighted image (see figure 4). Such
early detection of changes in the numerous lesion
markers is likely to increase the predictive value of
the MRS method. In contrast, a low NAA-to-Cho ra-
tio was identified as the sole predictor of C-ALD
progression in a retrospective MRS imaging (MRSI)
study.28 Although the coverage of whole brain slices
by the MRSI technique may be advantageous in dis-
eases where the locations of lesion development are
more uncertain, such as multiple sclerosis, the ex-
tensive profile provided by single voxel spectroscopy
outweighs this advantage in a disease like ALD
where all sites of possible cerebral involvement can
be covered in a reasonably short scan time. Another
major advantage of single voxel spectroscopy over
MRSI is that the effects of motion can be minimized.
The current study extended previous reports of
low NAA, high Cho, and myo-Ins,8,9,13 as well as occa-
sional observations of high Lac8,9,12-14 and lipids12,13,29
in ALD lesions. Surprisingly, Cho and Cr, two com-
pounds extensively used in assessing abnormalities,
were the weakest markers (see figure 2; also see p
values and number of lesions that were more than 2
SD different from adult controls in table 1). Despite
the evaluation of the sum of Lipid and Lac, due to
the overlap of their signals at 1.3 ppm, this mea-
surement was one of the best markers of advancing
disease (see figure 3A). The Lipid  Lac increase
was probably due to both lactate and mobile lipids
because we detected a lactate doublet with the ex-
pected 7 Hz homonuclear coupling in some patients
(see figures 1 and 3). A reduction in Cr was observed
in one other study in advanced lesions.9 Similarly,
the decrease in Glu and increase in Gln were ob-
served in one previous study, but only when using
group averages.9 In the present study Glu and Gln
were reliably measured in individual patients with
ALD for the first time and their ratio was highly
sensitive to the presence of lesions (see figure 2).
These results indicate that several major features
of ALD pathology can be assessed in individual pa-
tients using MRS at 4 tesla, including neuroaxonal
loss, gliosis, demyelination, and macrophage infiltra-
tion.1 Reduced NAA and Glu levels in lesions are
likely a result of neuroaxonal loss while increased
Gln and myo-Ins are possibly associated with glio-
sis.9,30 Cho is thought to increase during active demy-
elination,9 whereas increases in lactate have been
ascribed to the anaerobic metabolism of infiltrating
macrophages.8,9,12-14 Reduced Cr may indicate distur-
bances in energy metabolism.
Of special interest was the assessment of a lipid
contribution to the lesion spectra since ALD is a
disorder of lipid metabolism. Incomplete elimination
of intense subcutaneous fat signals may confound
accurate measurement of mobile lipids in the brain.8
In our data, the signals of the mobile lipids were
in-phase relative to the rest of the spectrum and the
lipid contribution was consistently observed in all
lesions but never in healthy tissue, indicating that
the lipid resonances originated from the VOI. Fur-
Figure 5. Decrease of glutamine (A) and lipids  lactate
(B) in occipital white matter lesions over time after hema-
topoietic cell transplantation (HCT). The different symbols
represent different patients. HCT was performed at t  0.
All patients were scanned before HCT, however in two
cases (e , ‚) spectra were not acquired in the same loca-
tions as after HCT, therefore only data after HCT are
shown.
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thermore, the localization method used herein pro-
vides a high degree of subcutaneous lipid signal
suppression. An intriguing question is whether the
detected mobile lipid resonances stem from the satu-
rated VLCFA that accumulate in ALD, as suggested
earlier.13 We tentatively ascribed the lipid contribu-
tion to a mixture of saturated and monounsaturated
fatty acids since the spectra displayed a small peak
at 5.3 ppm indicative of double bonds, but none at
2.8 ppm indicating lack of polyunsaturated fatty ac-
ids.31 Furthermore, the methyl-to-methylene ratio
corresponded to short fatty acyl chains suggesting
that the lipid resonances appear due to increased
turnover of myelin lipids, rather than VLCFA accu-
mulation. However, binding of VLCFA to large struc-
tures in the cell, such as the proteolipid protein, may
also result in the observed methyl-to-methylene ra-
tio. Furthermore, the evidence for unsaturation in
our data does not rule out the possibility that the
detected lipids represent VLCFA since monounsatu-
rated VLCFA increase in phospho- and proteolipids
and gangliosides in the ALD brain along with satu-
rated VLCFA.1
Biochemical alterations were present in the ALD
brain even in the absence of cerebral disease (see
table 1). Among these, decreased NAA was previ-
ously reported.8,15 A significant increase in Lipid 
Lac and decrease in Cr were detected. The increase
of Lipid  Lac may be an indication of increased
VLCFA in intact brain regions as observed previ-
ously by histopathology.1 Other differences between
NAWM of patients with ALD and adult controls
(GSH, PE, and Glc  Tau) were possibly due to the
difference in age. However, these metabolites are not
strongly represented in the spectra and more sub-
jects are necessary to determine whether these me-
tabolites change developmentally in the age range (4
to 13) of this study. Although most metabolic
changes in the developing human brain appear to
occur in the first 2 to 3 years,32-34 to our knowledge no
studies have evaluated the current neurochemical
profile in the same age range.
We followed neurochemical changes in response to
HCT, for which MRI may not be the ideal tool.35
Indeed, in patients who had undergone HCT the hy-
perintense regions on T2-weighted images after
transplant were either similar to or more extensive
than those before HCT. Conversely, some metabolite
concentrations that were abnormal prior to HCT ap-
proached control values after HCT and continued to
improve over time (see figure 5). Our results after
HCT agree with and extend previous observations in
two studies that reported decreased Cho, conserved
or decreased NAA, and conserved or increased myo-
Ins.9,36 We measured three additional metabolites
(Glu, Gln, Lipid  Lac) that changed after the HCT
and the consistent reduction of two of these (Gln,
Lipid  Lac) suggested improvements in the neuro-
chemical profile. Which of these markers is associ-
ated with a good outcome in the long term remains
to be determined.
In previous studies the reduced Cho levels after
HCT were interpreted as arrested demyelination and
the high myo-Ins as a consequence of remaining high
content of glial cells and further reactive gliosis.9,36
However, the normalized Gln concentrations, if
taken to represent glial cell volume, suggest reversal
of gliosis. Alternatively, the restored Gln concentra-
tions could result from a metabolic adaptation by the
brain. Myo-Ins, on the other hand, is involved in a
number of different functions in the cell, from serv-
ing as a precursor for lipid synthesis to acting as an
idiogenic osmolyte.37 Therefore, myo-Ins concentra-
tion may not exclusively reflect glial volume. The
decrease of Lipid  Lac levels may be due to the
mobile lipids having been metabolized by the donor
microglia that entered the brain as a result of the
HCT.38 Even though Lac decreases following HCT
were conceivable, the characteristic doublet at 1.3
ppm was still visible in some patients (see figure 4),
suggesting that lactate remained elevated since it is
difficult to detect in normal brain tissue. Finally, the
unchanged/reduced Glu and NAA concentrations af-
ter the HCT were consistent with an irreversible loss
of neuronal tissue.
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